公开(公告)号：EP3763712A1

公开(公告)日：2021-01-13

申请号：EP19763371.2

申请日：2019-03-05

申请人： Shanghai Haihe Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： CHEN, Xuxing ,  CHEN, Yi ,  HUANG, Ying ,  GENG, Meiyu ,  ZHANG, Qiong ,  DING, Jian ,  YAO, Yucai ,  SHEN, Qianqian ,  SHEN, Yanyan

IPC分类号： C07D471/04 ,  C07D519/00 ,  C07D471/14 ,  C07D491/147 ,  A61K31/444 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4545 ,  A61P35/00 ,  A61P37/06

摘要： The invention provides an indolizine compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method and a use thereof. The indolizine compound has an inhibitory effect on wild-type and/or mutant EZH2 or EZH1, and is expected to be developed into a novel drug for anti-tumor or for the treatment of autoimmune diseases.

公开(公告)号：EP3702354A1

公开(公告)日：2020-09-02

申请号：EP18862819.2

申请日：2018-09-29

申请人： Shanghai Haihe Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： LI, Lei ,  GENG, Meiyu ,  HUANG, Ying ,  DING, Jian ,  ZHANG, Qiong ,  HUANG, Min ,  TANG, Shuai ,  SHEN, Ning ,  CHEN, Yi

IPC分类号： C07D403/14 ,  C07D401/14 ,  A61K31/506 ,  A61K31/404 ,  A61P35/00

摘要： The invention relates to a compound of formula (I):

wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.